title: Management of Dabigatran-Associated Bleeding with Two Doses of Idarucizumab Plus Hemodialysis.
abstract: Vitamin K antagonists have been a mainstay of treatment for patients requiring anticoagulation for atrial fibrillation, but direct oral anticoagulants, such as dabigatran, have become increasingly prescribed. Compared with warfarin, dabigatran has a significantly lower risk of life-threatening bleeding; however, bleeding events can still occur, supporting the need for effective reversal strategies. Idarucizumab was recently approved by the U.S. Food and Drug Administration to reverse the anticoagulant effects of dabigatran when life-threatening bleeding occurs or an urgent need for an invasive medical procedure exists. Before idarucizumab's approval, reversal strategies included hemodialysis, coagulation factor replacement, and, in the setting of acute ingestion, activated charcoal. We describe the case of a 58-year-old, obese woman with a history of atrial fibrillation who developed acute kidney injury while taking dabigatran 150 mg twice/day, resulting in coagulopathy. Despite receiving idarucizumab 5 g and hemodialysis, there was a rebound increase in prothrombin time (PT) and activated partial thromboplastin time (aPTT) values, prompting administration of an additional 5-g dose of idarucizumab and continued hemodialysis, with subsequent PT and aPTT values remaining within their appropriate ranges. To our knowledge, this is the first case report to describe the successful use of repeat dosing of idarucizumab with hemodialysis to reverse the anticoagulant effects of dabigatran. Although two doses of idarucizumab were given to our patient, this dosing regimen is not the current standard of practice. Administration of idarucizumab and the use of additional reversal strategies should involve an assessment of each individual patient's severity of bleeding and subsequent risk of thrombosis. Due to the recent availability of idarucizumab and varying success with alternative reversal strategies, additional knowledge is needed for the optimal reversal of anticoagulation from dabigatran.
authors: Department of Pharmacy, Brigham and Women's Faulkner Hospital, Jamaica Plain, Massachusetts. kkmarino@partners.org.
authors: Kaylee K
authors: KK
authors: Marino
authors: Department of Pharmacy, Brigham and Women's Faulkner Hospital, Jamaica Plain, Massachusetts.
authors: Raul A
authors: 0000-0003-1422-1480
authors: RA
authors: Santiago
authors: Department of Pharmacy, Brigham and Women's Faulkner Hospital, Jamaica Plain, Massachusetts.
authors: Richard B
authors: RB
authors: Dew
authors: Department of Medicine, Division of Hematology, Brigham and Women's Hospital, Boston, Massachusetts.
authors: Nancy
authors: N
authors: Berliner
authors: Department of Medicine, Division of Hematology, Brigham and Women's Hospital, Boston, Massachusetts.
authors: Jean M
authors: JM
authors: Connors
authors: Department of Medicine, Division of Hematology, Brigham and Women's Hospital, Boston, Massachusetts.
authors: Nathan T
authors: NT
authors: Connell
authors: Department of Medicine, Division of Nephrology, Brigham and Women's Faulkner Hospital, Jamaica Plain, Massachusetts.
authors: John Kevin
authors: JK
authors: Tucker
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage*; D000931:Antidotes / Q000008:administration & dosage; D000991:Antithrombins / Q000008:administration & dosage / Q000009:adverse effects; D001281:Atrial Fibrillation / Q000188:drug therapy; D003131:Combined Modality Therapy; D000069604:Dabigatran / Q000008:administration & dosage / Q000009:adverse effects*; D005260:Female; D006470:Hemorrhage / Q000139:chemically induced / Q000628:therapy*; D006801:Humans; D008875:Middle Aged; D006435:Renal Dialysis / Q000379:methods*; D016896:Treatment Outcome
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000931:Antidotes; D000991:Antithrombins; C000594745:idarucizumab; D000069604:Dabigatran
keywords: dabigatran; hemodialysis; idarucizumab; toxicity